Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02982707 · ClinicalTrials.gov registry record · Phase 1
Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT02982707 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 26 participants.
The verdict
NCT02982707, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
A single oral dose of BMS-986177 administered to subjects of mild hepatic impairment, moderate hepatic impairment and healthy matched subjects to evaluate pharmacokinetics, safety, and tolerability in these subjects
Interventions
- DRUG BMS-986177
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2018-09-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02982707
The ClinicalTrials.gov registry entry for NCT02982707 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-986177 is the first listed.
NCT02982707 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02982707 about?
NCT02982707 is a clinical study titled "Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants". A single oral dose of BMS-986177 administered to subjects of mild hepatic impairment, moderate hepatic impairment and healthy matched subjects to evaluate pharmacokinetics, safety, and tolerability in these subjects
What is the current status of trial NCT02982707?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2018-03-01. Estimated completion is 2018-09-28.
What interventions are being tested in trial NCT02982707?
The interventions under investigation include: BMS-986177 (DRUG).
Who is sponsoring clinical trial NCT02982707?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.